Industry News

Bioresonance, an alternative therapy for mild and moderate depression

Depression is the most common of the affective disorders and belongs to the field of psychiatry. Depression is defined more as a mood disorder than a thought disorder that limits an individual's normal functioning and can range in form from very mild to severe.
This negative emotional state can last for a short time or for a long time, with mild, moderate or severe intensity, and can seriously damage people's health. Globally, depression, along with cardiovascular disease and cancer, is a leading cause of premature death, limits an individual's activities, and carries a significant suicide risk. Nearly 800,000 people die by suicide each year. 5% of Europeans suffer from depression and 25% are likely to experience depression at least once in their lifetime. Depression is projected to become one of the most serious mental and behavioral disorders by 2030 and is currently the second-highest disease worldwide, after cardiovascular disease.
About 80% of people with mental illness go untreated, especially in less developed countries. The most common treatments for depression are medication and antidepressants, either in combination with psychotherapy, or psychotherapy as a monotherapy. Each treatment was found to be useful, but for patients with major depressive disorder, high withdrawal rates and low remission rates were found, and clinically significant differences were observed between antidepressants and placebo. Therefore, patients with mild or moderate depression seek alternative treatments.
Since 1970, bioresonance therapy has been successfully used by many practitioners around the world as an alternative therapy for a variety of ailments. Global research teams have completed multiple clinical, physical and organic studies demonstrating the effectiveness of bioresonance methods in conditions such as allergies, rheumatic diseases, respiratory diseases and many pain syndromes.
The analysis group for this study consisted of women and men from different social backgrounds, aged 18 to 89 years (mean 49 years/SD 17.16 years). Patients with a history of suicide attempts, pacemaker use, and pregnant women were excluded.
Participants were divided into two groups as follows: Group 1 included 40 patients (31 women and 9 men), 17 women with recurrent mild depressive episodes and 14 women with recurrent moderate depressive episodes . In the category of males, 4 males had recurrent moderate depression and 5 males had recurrent minor depression. They receive only Biophilia Tracker for bioresonance therapy. Group 2 included 40 patients (19 females and 21 males). All study participants in this group had previously been diagnosed with recurrent moderate depressive disorder. They received monotherapy with selective serotonin reuptake inhibitor antidepressants.
For all patients, reductions in depression levels were monitored from the first to the fifth treatment over a period of up to two months.
The first set of bioresonance treatments lasts 20 minutes and is performed using the Biophilia Tracker.
The second group received selective serotonin reuptake inhibitor (SSRI) monotherapy.
In the present study, in the first group of patients, 4 men and 10 women improved from a moderately depressive state to a mildly depressive state after five sessions of bioresonance therapy. Among the study participants in the second group, both women and men were moderately depressed.
The findings confirm that bioresonance therapy using the Biophilia Tracker can improve the condition of mild and moderate recurrent depression patients who have not opted for medication.